How do I know if I'm in perimenopause if I'm still getting periods?

Perimenopause is defined by the change pattern, not by absence of periods. If your cycles have shifted in length by seven days or more from your usual, or you're getting new symptoms like hot flashes, night sweats, sleep disruption, or new mood changes in your 40s, that's the picture. You can be in perimenopause for four to ten years before your final period.

Do I need a hormone test to confirm it?

Usually no. The North American Menopause Society and ACOG both recommend a clinical diagnosis based on age and symptoms, not lab values. FSH and estradiol levels swing wildly during perimenopause and a single number rarely changes management. We test thyroid function, ferritin, vitamin D, and sometimes A1C to rule out look-alike conditions.

Is HRT safe? Didn't a study say it causes breast cancer?

The 2002 Women's Health Initiative findings have been re-examined extensively. For healthy women under 60 or within 10 years of menopause, the absolute risks of modern HRT are small, and the benefits for hot flashes, sleep, bone, and quality of life are substantial. Risk varies by formulation, route of administration, age at initiation, and personal history. We walk through your specific risk profile before prescribing.

What does HRT cost and is it covered?

FDA-approved oral and transdermal estradiol, micronized progesterone, and combination patches are typically inexpensive generics, often $10 to $40 per month with insurance, and many plans cover them. Bioidentical compounded preparations cost more and aren't recommended as first-line by ACOG or the Menopause Society. We start with FDA-approved products.

Can I get evaluated and treated by telehealth?

Often yes. We do new-patient perimenopause and menopause visits by telehealth in states where Dr. Harris is licensed, including Florida, California, Nevada, Texas, Arizona, New York, Illinois, Washington, Colorado, and several others. We need labs (which can be drawn locally) and a recent blood pressure reading, and we usually arrange a baseline mammogram per ACOG guidelines if one isn't current.

What if I want to stop HRT later?

Most women take HRT for several years, then taper down. There's no fixed end date. We don't recommend stopping abruptly, since hot flashes often return within weeks. Tapering over a few months, with adjustments based on symptoms, is the typical approach. The decision to continue is reviewed annually.

Perimenopause Symptoms and HRT, Explained: A Clinician's Guide for Women 40 to 55

You went to bed at 10 p.m. like a reasonable person. Now it's 3:14 a.m., the sheets are damp, you're wide awake, and you've already done tomorrow's mental to-do list twice. Your last period was 24 days after the previous one. Or 41. You can't tell anymore. Your jeans don't fit the way they did a year ago, even though you haven't changed how you eat. You snapped at your kid yesterday for something small and didn't recognize the version of yourself who did that.

If any of this feels familiar, you're probably in perimenopause, and you're probably tired of being told it's just stress, or just aging, or just a phase. It is a phase, but that doesn't mean you have to white-knuckle through it. The biology is well-understood, the treatments are real, and the safety data on hormone therapy looks very different than what your mother was told twenty years ago. This article walks through what's actually happening in your body, what the evidence says about treatment, and what an honest conversation about hormone therapy looks like.

What perimenopause actually is

Menopause itself is a single point in time: the day you've gone twelve months without a menstrual period. The average age in the United States is 51, with a normal range of roughly 45 to 55. Perimenopause is the years leading up to that point, when ovarian function is becoming irregular but hasn't stopped, and it can last four to ten years [6][8].

The hormonal picture is messy. In a regular reproductive cycle, estrogen rises in the first half of the cycle, ovulation happens, and progesterone rises in the second half. In perimenopause, ovulation becomes inconsistent. Estrogen swings between very high and very low, often within the same cycle. Progesterone production falls earlier and more dramatically than estrogen does, because progesterone depends on ovulation actually happening. The result is a pattern that looks chaotic on paper and feels chaotic in the body [8][10].

This is why a single FSH or estradiol level rarely tells you anything useful. You can have a "normal" estradiol on Tuesday and a postmenopausal one on Friday. ACOG and the North American Menopause Society both recommend diagnosing perimenopause clinically, based on age, cycle changes, and symptoms, not on a single lab value [1][2].

The classic diagnostic threshold from STRAW (Stages of Reproductive Aging Workshop) is a persistent change in cycle length of seven or more days from your typical pattern, plus or minus other symptoms. If your cycles have always been 28 days and they're now ranging from 24 to 35, you're likely in early perimenopause.

The symptoms that actually show up

Hot flashes and night sweats are the textbook symptoms, and they're real. About 75 percent of women in perimenopause and menopause experience vasomotor symptoms (hot flashes and night sweats), and for roughly a third, the symptoms are moderate to severe enough to interfere with sleep, work, or quality of life [2][6]. Average duration is around seven years, with some women experiencing them for over a decade.

The symptoms that surprise people are the ones that don't fit the textbook:

Sleep disruption that isn't only night sweats. Perimenopausal sleep often fragments, with frequent 2 to 4 a.m. awakenings, even on nights without sweating. Estrogen and progesterone both modulate GABA and serotonin pathways involved in sleep, and the swings disturb sleep architecture independently of temperature [2].

Mood changes that look like new-onset anxiety, low mood, or irritability in women with no prior history. This is real and often underdiagnosed. The risk of a major depressive episode roughly doubles during the menopausal transition, particularly in women with a prior history [10].

Cognitive changes, often described as brain fog, word-finding difficulty, or mild short-term memory issues. Most women return to baseline after the menopausal transition, but the experience during it is unsettling and gets dismissed too often.

Weight redistribution and weight gain. A meta-analysis of midlife weight changes shows women gain an average of 1.5 pounds per year during the menopausal transition, with a shift in fat distribution toward the abdomen. Falling estrogen reduces resting metabolic rate slightly and changes insulin sensitivity, which affects body composition independent of caloric intake [10].

Vaginal and urinary changes, called genitourinary syndrome of menopause (GSM). Vaginal dryness, painful intercourse, urinary urgency, and recurrent UTIs all reflect estrogen-dependent tissue changes and they don't resolve on their own.

Joint pain. Many women in perimenopause develop diffuse joint and muscle aches that don't fit a clear arthritis pattern. Estrogen modulates inflammation and pain signaling, and the symptoms often improve with hormone therapy [2].

Cardiovascular shifts. Cholesterol, blood pressure, and visceral fat all tend to worsen across the menopausal transition. The 10-year cardiovascular risk meaningfully rises post-menopause, which is why this window is also a useful one for cardiovascular prevention.

If you're nodding along to half of these, you're not imagining it.

What hormone therapy actually does

Modern hormone therapy (HRT, sometimes called MHT for menopausal hormone therapy) replaces some of the estrogen and, when the uterus is intact, progesterone, that the ovaries are no longer producing reliably. The goals are symptom control, bone protection, and quality of life, not turning back the clock.

The evidence is strong for several outcomes:

Vasomotor symptoms. HRT is the most effective treatment for hot flashes and night sweats, reducing frequency by 75 percent or more in most women [2][4][5].
Sleep. Symptom-driven sleep disruption typically improves substantially within weeks of starting therapy [2].
Bone density. HRT reduces fracture risk meaningfully, including hip fractures, and is FDA-approved for osteoporosis prevention in appropriate candidates [2][7].
Genitourinary syndrome. Local vaginal estrogen, in low doses, is highly effective for vaginal dryness, painful sex, and recurrent UTIs, with negligible systemic absorption [1][2].
Mood symptoms. For perimenopausal-onset depression and anxiety, transdermal estradiol with or without progesterone has supportive trial data, often used alongside SSRIs in moderate-to-severe cases [10].

Evidence is more nuanced for:

Cognitive function. No clear evidence that HRT prevents dementia. Starting HRT in your 50s when symptomatic does not appear to harm cognition, but starting it for the first time in your 70s for cognitive protection is not supported.
Cardiovascular disease. When HRT is started within ten years of menopause or before age 60, cardiovascular outcomes appear neutral to mildly favorable. Starting it more than ten years out is a different risk profile [2][3].
Skin and hair. Modest improvements are reported but not the primary indication.

The Women's Health Initiative, in plain terms

The 2002 WHI publication caused a generation of clinicians to stop prescribing HRT and a generation of women to stop taking it. The story is more complicated than the headlines suggested.

The WHI enrolled women whose average age was 63, well past the typical onset of menopause, and used oral conjugated equine estrogens (Premarin) plus medroxyprogesterone acetate (Provera) as the test combination. The combined-therapy arm showed a small absolute increase in breast cancer (about 8 additional cases per 10,000 woman-years), a small increase in venous thromboembolism, and no overall reduction in cardiovascular events, leading to early termination of that arm.

What followed-up analyses have shown:

Age and timing matter. Women who started HRT within ten years of menopause or before age 60 had different outcomes than the older cohort, with cardiovascular and mortality outcomes looking neutral to favorable [3].
Estrogen-alone (in women without a uterus) didn't show the same breast cancer signal. The WHI estrogen-alone arm showed no significant increase in breast cancer over 18 years of follow-up [3].
Route of administration matters. Transdermal estradiol does not appear to carry the same VTE or stroke risk as oral conjugated estrogens, because it bypasses first-pass liver metabolism.
Progestin choice matters. Micronized progesterone (Prometrium), which is the molecule the body actually produces, has a more favorable breast and cardiovascular profile than synthetic progestins like medroxyprogesterone.

The 18-year follow-up of WHI showed no increase in all-cause mortality from HRT in either arm, even with the breast cancer signal in the combined arm [3]. The North American Menopause Society 2022 position statement, ACOG, and the Endocrine Society now agree: for healthy symptomatic women under 60 or within 10 years of menopause, the benefits of HRT generally outweigh the risks [1][2][4].

Who is and isn't a candidate

HRT is reasonable for symptomatic women who are:

Within 10 years of their last period or under 60
Without a personal history of breast cancer, estrogen-receptor-positive cancer, unexplained vaginal bleeding, active liver disease, recent VTE or stroke, or known thrombophilia
Willing to engage in shared decision-making about a several-year therapy

HRT is generally not first-line for women with:

Personal history of breast cancer or hormone-sensitive cancer
Recent or recurrent VTE or stroke
Active liver disease
Coronary artery disease, particularly when initiated more than 10 years post-menopause
Pregnancy (though this rarely applies in this age group)

For women who can't or don't want to take systemic HRT, there are real alternatives. SSRIs (paroxetine is FDA-approved for hot flashes), SNRIs, gabapentin, oxybutynin, and the newer NK3 receptor antagonist fezolinetant (Veozah) all have evidence for vasomotor symptoms. Cognitive behavioral therapy for insomnia and for hot flashes is genuinely effective and underused [2].

For genitourinary symptoms specifically, low-dose vaginal estrogen (cream, ring, or tablet) is safe even in many women who can't take systemic HRT, including most breast cancer survivors after individualized discussion with their oncologist.

What about "bioidenticals" and compounded hormones?

The term "bioidentical" technically means a hormone with a molecular structure identical to what the body produces. By that definition, FDA-approved estradiol patches, micronized progesterone capsules (Prometrium), and combination products like Bijuva are bioidentical. These are well-studied, regulated, and inexpensive.

The marketing term "bioidentical hormone therapy" usually refers to compounded hormones, often pellets or custom creams sold by clinics that test "hormone levels" and claim to tailor a unique formula. ACOG, the Endocrine Society, and the North American Menopause Society all advise against compounded bioidentical HRT as first-line, because:

Compounded products are not FDA-approved, so quality, dosing accuracy, and absorption vary
The "personalized testing" model isn't supported by evidence; saliva and serial blood levels don't predict symptom response or safety
Compounded products often lack adequate progestin, which raises endometrial cancer risk in women with a uterus
Pellets in particular produce supraphysiologic estradiol levels that aren't recommended [9]

If you've been told you need compounded hormones because FDA products won't work for you, that's a conversation worth revisiting. The vast majority of women do well on standard FDA-approved formulations.

Practical action plan

If you suspect you're in perimenopause and you want to know what to do this week:

Track symptoms for two cycles. Note cycle length, hot flashes (frequency and severity), sleep quality, mood, and any new symptoms. A simple notes app entry per day is enough.
Ask for the right labs at your next visit. TSH (rule out thyroid disease, which mimics perimenopause), ferritin (rule out iron deficiency, very common in heavy perimenopausal periods), vitamin D, fasting lipids and A1C if not done in the last year. FSH and estradiol are usually optional.
Get a baseline blood pressure reading and an updated mammogram if not current per ACOG guidelines.
Look at lifestyle leverage points. Resistance training two to three times weekly, protein at 1.0 to 1.2 grams per kilogram of body weight, alcohol intake (a major hot flash and sleep trigger), and sleep hygiene. None of these replaces HRT for moderate-to-severe symptoms, but all of them stack with treatment.
Schedule a perimenopause-specific visit. A 15-minute physical isn't enough time to do this well. Look for a clinician who'll spend 30 minutes on history and shared decision-making.

What we do at Nomi Beach Health

Our women's health and HRT visits are built around the recognition that perimenopause is a multi-year transition, not a single event, and that treatment evolves over time. A new-patient evaluation includes:

A full symptom and cycle history, plus relevant cardiovascular, breast cancer, and clotting history
Targeted labs (TSH, ferritin, vitamin D, lipids, A1C, plus reproductive hormones only when clinically useful)
Review of current contraception, since perimenopausal women can still get pregnant, and some HRT regimens are not contraceptive
A shared-decision conversation about whether HRT, non-hormonal medication, or behavioral approaches fit your situation, with the actual data on each
A specific starting plan, usually transdermal estradiol with micronized progesterone if you have a uterus, dosed to symptom control
Local vaginal estrogen for genitourinary symptoms when present
Follow-up at six to eight weeks to titrate, with annual reviews thereafter
Coordination with your gynecologist, primary care, and any oncology or cardiology clinicians

We use FDA-approved estradiol patches, sprays, gels, and tablets, plus micronized progesterone (Prometrium) or combination products like Bijuva. We don't use compounded hormone pellets. Telehealth visits are available in the states where Dr. Harris is licensed, with labs drawn locally.

Closing nudge to consult

If you've spent the last two years being told "your labs are fine" while you can't sleep, can't think, can't fit your clothes, and don't recognize your own mood, you deserve a real conversation. Perimenopause is one of the most under-treated conditions in primary care, partly because it's diffuse, partly because of a generation of WHI-era caution that hasn't fully updated, and partly because a 15-minute appointment isn't enough time to address it.

Schedule a visit and we'll go through your symptoms, your labs, your goals, and the actual evidence. Treatment isn't right for everyone, but a clear-eyed look at the options is a reasonable thing to ask for in your forties.